AMTAGVI Gets FDA Patent Boost: Challenge by August 2026
Published Date: 2/13/2026
Notice
Summary
The FDA has officially set the review period for AMTAGVI, a new human biological product, so its patent can be extended. This affects the company behind AMTAGVI and anyone interested in patent timing or drug availability. If you think the dates are wrong or want to challenge the company’s diligence, you have until April 14 or August 12, 2026, to speak up—so don’t miss these deadlines!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
AMTAGVI Review Period Set
The FDA determined AMTAGVI's regulatory review period is 3,306 days in total: 2,969 days in the testing phase and 337 days in the approval phase. FDA verified the testing phase began on January 30, 2015, the biologics license application was submitted on March 17, 2023, and the application was approved on February 16, 2024. This determination establishes the maximum potential length of a patent extension; the applicant is seeking 42 days of patent term extension and the USPTO will apply statutory limits when calculating the actual extension.
Deadlines To Challenge Dates
Anyone who believes the published dates are incorrect may submit comments and ask for a redetermination by April 14, 2026. Any interested person may petition FDA about whether the patent applicant acted with due diligence during the regulatory review period by August 12, 2026, and petitions must meet the requirements of 21 CFR 60.30 and related filing rules.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-02973 — Determination of Regulatory Review Period for Purposes of Patent Extension; CRENESSITY
The FDA has officially set the review period for CRENESSITY, a new drug, so its patent can be extended. This helps the drug maker get extra time to protect their invention, which could affect when generic versions hit the market. If anyone thinks the dates are wrong or wants to challenge the drug maker’s speed during review, they have until April 14 or August 12, 2026, to speak up.
Next: 2026-02976 — Determination of Regulatory Review Period for Purposes of Patent Extension; KEBILIDI
The FDA has set the official review period for KEBILIDI, a human biological product, so its patent holder can apply for extra patent time. This helps the company protect their invention longer, potentially affecting when generic versions can enter the market. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until April or August 2026 to speak up.